Skip to main content

Table 2 Performance of PIVKA-II for the diagnosis of AFP-negative HCC patients

From: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma

  AUC(95%CI) Cutoff value Sensitivity(%)(95%CI) Specificity(%)(95%CI)
HCC vs Healthy controls 0.88 (0.82–0.94) 38.75mAU/ml 78.33 (66.38–86.88) 91.3 (85.42–94.96)
HCC vs Benign liver diseases 0.76 (0.67–0.85) 42.07 ng/ml 74.19 (62.12–83.45) 82.68 (75.16–88.27)